In accordance with in vitro results, the levels of Hes5 proteins in tumor tissues were considerably decreased after mice received various doses of fidaxomicin, suggesting a possible RBPJ-dependent inhibitory mechanism of action. The gene discussed is HES5; the disease is neoplasm.